Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses

Harno-Tasihin, Jenniina; Siregar, Laura; Paajanen, Mikko; Arkkila, Perttu; Punkkinen, Jari

doi:10.1080/00365521.2023.2285229

Cited by 2 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to this perception, the multicenter, prospective SECURE study demonstrated that switching from IV to SC infliximab in patients with IBD in remission is safe and resulted in higher infliximab concentrations at 16 weeks in both UC and CD patients [ 18 ]. SC infliximab has been shown to maintain consistently higher levels of the drug and exhibit significantly lower immunogenicity [ 10 , 19 ], excluding those receiving IV infliximab at 10 mg/kg every four weeks [ 9 ]. Significant as well as level elevation was also documented with SC vedolizumab following such a switch [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…SC infliximab has been shown to maintain consistently higher levels of the drug and exhibit significantly lower immunogenicity [ 10 , 19 ], excluding those receiving IV infliximab at 10 mg/kg every four weeks [ 9 ]. Significant as well as level elevation was also documented with SC vedolizumab following such a switch [ 10 ]. Cerna et al proposed that SC infliximab may be a “Biobetter”, aiming to improve upon existing biologics therapies.…”

Section: Discussionmentioning

confidence: 99%

“…In Finland, economic factors were the main reason for IBD patients not switching from IV to SC therapy [ 10 ]. Contrary to Finland, where SC infliximab and vedolizumab are not fully reimbursed, in Israel, the patient’s deductible for the drug is the same price for SC and IV.…”

Section: Discussionmentioning

confidence: 99%

“…In light of recent publications underscoring the safety and efficacy of SC administration of medications that are suitable for IBD maintenance via both the IV and SC routes [ 4 , 5 , 6 , 7 , 8 , 9 ], and considering the significantly higher costs associated with IV delivery [ 10 ], it is unequivocally in the best interest of the health system to accelerate the transition toward SC administration. The current trend of starting maintenance therapy with SC regimens implies that SC delivery will soon be the primary mode of treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Patient preferences are influenced by various factors, including cost [ 10 ] and the distance from the outpatient infusion facilities [ 13 ]. The Israeli health system, founded on a universal healthcare model, contains a “Health Basket”, which comprises a list of medications that are covered by national health insurance, ensuring access to essential pharmaceuticals.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Richter,

Cohen,

Kriger-Sharabi

et al. 2024

JCM

View full text Add to dashboard Cite

Biological inflammatory bowel disease (IBD) medications, once limited to intravenous (IV) administration, can now be administered both via IV and subcutaneously (SC). This study investigates patient preferences, willingness to switch from IV to SC, and associated factors. A questionnaire covering demographics, disease-related inquiries, quality of life, and IBD medication preferences was distributed via email, the Israeli Crohn’s Disease and Ulcerative Colitis Foundation, infusion centers, and clinics. From 454 IBD patients (median age: 42 years; 55.7% female), responses revealed a preference for SC every 8 weeks, which is comparable to daily oral dosing. Both options were significantly favored over IV every 8 weeks and SC every 2 weeks, with no statistically significant differences between the latter two. However, among patients who were experienced with both SC and IV administration, a clear preference for SC administration every 2 weeks over IV every 8 weeks surfaced. Among IV-treated patients, 54.5% resisted switching to SC. Key reasons for this included medical staff presence (57.7%), a fear of needles (46.4%), belief in infusion efficacy (37.1%), and longer intervals between infusions (36.1%). Findings suggest that transitioning from IV to SC treatment is challenging due to patient resistance, which is influenced by specific factors. Identifying and addressing these obstacles is crucial for optimizing IBD management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Richter,

Cohen,

Kriger-Sharabi

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations

Ferreira,

Lima Capela,

Arieira

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background Recently, a formula of subcutaneous infliximab (SC-IFX) has been approved for inflammatory bowel disease (IBD), demonstrating a better pharmacokinetic and immunogenic profiles, compared to intravenous infliximab (IV-IFX), with similar efficacy and safety. Aim The aim of this study is to evaluate the clinical, biochemical, and pharmacological outcomes of IBD patients in clinical remission, who switched from IV-IFX to SC-IFX, with a follow-up period of 6 months. Methods Retrospective cohort study, including IBD patients in clinical remission, previously medicated with IV-IFX, who switched to SC-IFX 120 mg every other week. Biochemical parameters were evaluated before the switch and 6 months after, namely infliximab serum concentrations, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal calprotectin. Results Included 41 patients in clinical remission, 32 with Crohn’s disease (78.0%) and 9 with ulcerative colitis (22.0%). All patients maintained clinical remission during the 6 months after the switch, with a treatment persistence rate of 100%, and no patients requiring corticosteroid therapy, switching back to IV-IFX, or IBD-related hospitalization. The mean infliximab serum concentrations were significantly higher after 6 months of SC-IFX (17.3 ± 6.6 vs. 9.1 ± 5.5 µg/ml, P < 0.001). However, there were no differences between values of ESR, CRP, and fecal calprotectin, before and after the switch (P = 0.791, P = 0.246, and P = 0.639). Additionally, none of the patients developed antibodies to infliximab. Conclusion Switching from IV-IFX to SC-IFX in IBD patients in clinical remission is effective and leads to higher infliximab serum concentrations, regardless of the combination with immunomodulatory therapy.

show abstract

Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses

Cited by 2 publications

References 23 publications

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations

Contact Info

Product

Resources

About